Health
Rapid generation of divergent synthetic antibodies against SARS-CoV-2 in a cell-free engineering platform – News-Medical.Net
In a groundbreaking bioRxiv paper, a research group from the Massachusetts Institute of Technology (MIT), Harvard University and Howard Hughes Medical Institute…
In a groundbreaking bioRxiv* paper, a research group from the Massachusetts Institute of Technology (MIT), Harvard University and Howard Hughes Medical Institute in the US engineered antibodies against the receptor-binding domain (RBD) of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike glycoprotein by using a novel approach. In doing so, they also identified more than 800 predicted binder families.
The ongoing coronavirus disease (COVID-19) pandemic is caused by the SARS-CoV-2,…
-
Noosa News9 hours agoConsolidated Pastoral Company buys Beetaloo aggregation in historic deal worth more than $300m
-
Business21 hours agoWhat Warren Buffett’s latest portfolio moves say about the market
-
Noosa News16 hours agoCibaria Noosa, Noosa Heads Review
-
Business15 hours agoCounter drone company surges past $1 billion valuation with new contract win